series-c-plus
Stage
2020
Founded
3
Investors
About
Glycomine is a biotechnology company focused on developing replacement therapies for rare genetic diseases, specifically targeting phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG) with its lead candidate GLM101, a mannose-1-phosphate replacement therapy.
Explore Glycomine's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.